POLICY STATEMENT

Recommendations for the Prevention of Perinatal Group B Streptococcal (GBS) Disease

abstract

The Centers for Disease Control and Prevention (CDC) guidelines for the prevention of perinatal group B streptococcal (GBS) disease were initially published in 1996. The American Academy of Pediatrics (AAP) also published a policy statement on this topic in 1997. In 2002, the CDC published revised guidelines that recommended universal antenatal GBS screening; the AAP endorsed these guidelines and published recommendations based on them in the 2003 Red Book. Since then, the incidence of early-onset GBS disease in neonates has decreased by an estimated 80%. However, in 2010, GBS disease remained the leading cause of early-onset neonatal sepsis. The CDC issued revised guidelines in 2010 based on evaluation of data generated after 2002. These revised and comprehensive guidelines, which have been endorsed by the AAP, reaffirm the major prevention strategy—universal antenatal GBS screening and intrapartum antibiotic prophylaxis (IAP) for culture-positive and high-risk women—and include new recommendations for laboratory methods for identification of GBS colonization during pregnancy, algorithms for screening and intrapartum prophylaxis for women with preterm labor and premature rupture of membranes, updated prophylaxis recommendations for women with a penicillin allergy, and a revised algorithm for the care of newborn infants. The purpose of this policy statement is to review and discuss the differences between the 2002 and 2010 CDC guidelines that are most relevant for the practice of pediatrics.

INTRODUCTION

Group B streptococcal (GBS) disease has been a leading cause of neonatal morbidity and mortality since the 1970s. Maternal colonization with GBS in the genitourinary or gastrointestinal tract and transmission to the infant during the labor-and-delivery process is the principal risk factor for early-onset invasive GBS disease. Women who are identified as being GBS-colonized through culture-based screening are more than 25 times more likely to deliver an infant with early-onset infection than are women with negative prenatal cultures. Identification of maternal colonization through universal, culture-based screening with intrapartum antibiotic prophylaxis (IAP) for women with positive screening results has been recommended since 2002. This strategy, endorsed by the American Academy of Pediatrics, has been widely adopted in the United States and has resulted in an estimated 80% decrease in early-onset GBS infection.
However, even in the era of universal screening, cases of GBS disease continue to occur. To evaluate data published after the Centers for Disease Control and Prevention (CDC) issued guidelines for the prevention of GBS perinatal disease in 2002, the CDC called a meeting of clinical and public health representatives in June 2009. The goal of the meeting was to identify potentially modifiable reasons for continued GBS disease and to address these issues. The American Academy of Pediatrics was represented by members of its Committee on Infectious Diseases and Committee on Fetus and Newborn. The purpose of this policy statement is to review and discuss the differences between the 2002 and 2010 CDC guidelines that are most relevant for the practice of pediatrics. Table 1 outlines the evidence-based rating system that supports each recommendation; strength (indicated by a letter) and quality (indicated by a roman numeral) of evidence are shown in parentheses. The 2010 CDC guidelines can be accessed online (www.cdc.gov/groupbstrep/guidelines/guidelines.html).

### LABORATORY DIAGNOSIS OF GBS COLONIZATION

The 2002 guidelines from the CDC recommended universal culture-based screening for GBS at 35 to 37 weeks of gestation. In the intervening years, new diagnostic technologies have been developed, including pigmented enrichment broths, chromogenic agars, DNA probes, and nucleic acid amplification tests (NAATs). These methods have been validated for antenatal testing for GBS colonization and are used in many clinical laboratories, which enables more rapid identification of GBS. A positive test result for GBS by culture, DNA probe, or NAAT performed during antenatal screening indicates colonization, and the woman should receive IAP. However, infants with early-onset GBS can be born to women with negative antenatal screening results, because all laboratory-screening methods are imperfect. Culture-based screening, especially if processing in the laboratory does not always follow the CDC guidelines, may not identify all colonized women. Infants with signs and symptoms of sepsis should be managed according to the neonatal algorithm (Fig 1) and receive an initial antibiotic regimen that includes ampicillin regardless of maternal screening results.

### Recommendations

- Options for GBS identification from culture of maternal vaginal/rectal swabs have been expanded to include a positive identification from chromogenic agar media. Identification of GBS directly by nucleic acid amplification tests (NAATs), such as commercially available polymerase chain reaction assays, can also be used after broth enrichment if laboratories have validated their NAAT performance and instituted appropriate quality controls (CII).

### INTRAPARTUM ANTIBIOTIC PROPHYLAXIS

Penicillin and ampicillin have each been demonstrated in controlled clinical trials to be effective in preventing early-onset GBS disease when administered during labor. Penicillin and ampicillin at the recommended dosages for IAP rapidly achieve therapeutic concentrations in the fetal circulation and then amniotic fluid. Cefazolin has similar pharmacokinetics when compared with penicillin, and IAP dos-
Signs of neonatal sepsis?  
- No

Maternal chorioamnionitis?  
- Yes

GBS prophylaxis indicated for mother?  
- Yes

Mother received ≥4 h of penicillin, ampicillin, or cefazolin IV?  
- Yes

≥37 wk and duration of membrane rupture < 18 h?  
- Yes

Either <37 wk or duration of membrane rupture ≥ 18 h?  
- Yes

Full diagnostic evaluation*  

Antibiotic therapy

Limited evaluation*  

Antibiotic therapy

Routine clinical care

Observation for ≥48 h

Observation for ≥48 h

Limited evaluation  

Observation for ≥48 h

Observation for ≥48 h

Recommendations

- Penicillin remains the agent of choice for IAP, and ampicillin is an acceptable alternative (AI).
- Penicillin-allergic women who do not have a history of anaphylaxis, angioedema, respiratory distress, or urticaria after administration of penicillin or a cephalosporin should receive cefazolin (BII).
- Penicillin-allergic women at high risk of anaphylaxis should receive clindamycin if their GBS isolate is susceptible or vancomycin if their GBS isolate is intrinsically resistant to clindamycin (CIII).
- The definition of adequate IAP has been clarified to be at least 4 hours of penicillin, ampicillin, or cefazolin. The initial intravenous dose of penicillin is 5 million units; for ampicillin and cefazolin, the initial dose is 2 g (AI).
- All other antibiotics, doses, or durations are considered inadequate for the purposes of neonatal management (AI).

Prevention of Early-Onset GBS Disease

The revised 2010 GBS American Academy of Pediatrics guidelines for neonatal management were designed to broaden the scope to include all neonates, to increase the clarity of the recommendations, and to decrease un-
necessary laboratory evaluations and empirical antibiotics for infants at low risk. Although this strategy will never prevent all infections, the revised guidelines should result in a further decrease in cases of perinatal GBS disease. The management of neonates continues to be based on clinical signs, the presence of maternal risk factors for GBS neonatal disease, and the likely efficacy of IAP (or maternal antimicrobial treatment in the case of clinical or occult chorioamnionitis) in preventing early-onset disease. The revised infant management algorithm (Fig 1) is derived from recent data summarized in the published CDC document regarding the epidemiology of GBS disease and the usefulness of a “limited evaluation” of well-appearing neonates.

All newborn infants with signs suggestive of sepsis should have a full diagnostic evaluation, including a lumbar puncture if the infant is stable enough to undergo the procedure; 15% to 38% of infants with early-onset meningitis have sterile blood cultures, so evaluating the cerebrospinal fluid is required for optimal diagnostic sensitivity.18–21 If the care provider believes that a noninfectious condition is responsible for the infant’s signs (eg, transient tachypnea of the newborn) and there are no maternal risk factors for sepsis in an otherwise well-appearing infant, the lumbar puncture can be deferred or eliminated. Empirical antimicrobial therapy, typically intravenous ampicillin and gentamicin (unless local antibiotic-resistance patterns suggest the need for another combination), then should be initiated promptly. Chorioamnionitis continues to be a significant risk factor for early-onset GBS sepsis in infants born to GBS-colonized women. All well-appearing newborn infants born to women who have a clinical diagnosis of chorioamnionitis from their obstetric provider should undergo a “limited evaluation,” which includes a complete blood cell (CBC) count and differential and a blood culture before initiation of empirical antimicrobial therapy. The sensitivity of the CBC count is improved if delayed for 6 to 12 hours after birth. Empirical therapy should be discontinued as soon as the clinical course and laboratory evaluation exclude sepsis.

The indications for maternal IAP remain unchanged and include 1 of more of the following: (1) GBS culture-positive within preceding 5 weeks; (2) GBS status unknown with 1 or more intrapartum risk factors including less than 37 weeks’ gestation, prolonged rupture of membranes for ≥18 hours, or temperature of ≥100.4°F (38.0°C); (3) GBS bacteriuria during current pregnancy; and (4) history of a previous infant with GBS disease. When a cesarean delivery is performed before onset of labor with intact amniotic membranes, the risk of early-onset GBS disease among infants is extremely low.23,24 Therefore, IAP is not recommended as a routine practice for cesarean deliveries performed under these circumstances, regardless of the GBS colonization status of the woman or the gestational age of the infant.

In well-appearing newborn infants born to women without an indication for IAP, routine clinical care is indicated unless signs of sepsis develop. For well-appearing term newborn infants born to mothers with an indication for IAP to prevent GBS disease and receipt of 4 or more hours of penicillin, ampicillin or cefazolin at the appropriate doses before delivery, routine care, and 48 hours of observation continue to be recommended. However, if these infants meet other discharge criteria, including term birth and ready access to medical care, discharge can occur as early as 24 hours after birth. In this latter circumstance, follow-up care by a care provider within 48 to 72 hours is recommended.

In well-appearing term newborn infants whose mothers had an indication for GBS prophylaxis and rupture of membranes for <18 hours but who received inadequate IAP—either by duration before delivery or by inappropriate agent or dose—observation in the hospital for at least 48 hours is recommended. These infants would include infants born to women with a serious penicillin allergy who received either clindamycin or vancomycin. This revised recommendation is based on the poor sensitivity of the “limited-evaluation” assessments in this circumstance and also data indicating that signs of early-onset GBS sepsis appear in more than 98% of neonates within this interval of hospitalization. The authors of several studies have reported the sensitivity of an abnormal CBC count in predicting GBS sepsis to range from 41% to 68%, whereas the presence of clinical signs has a sensitivity of 92%.24–27 The yield of blood culture can be low among newborn infants exposed to intrapartum antibiotics.28 Finally, for all preterm neonates (<37 weeks of gestation) or for term newborn infants born in the setting of rupture of membranes 18 hours or more before delivery without adequate maternal IAP, a limited evaluation and observation for at least 48 hours is recommended.

**Recommendations for Management of Newborn Infants**

- All newborn infants with signs of sepsis should undergo a full diagnostic evaluation (including a lumbar puncture) and receive empirical antimicrobial therapy (AII).
- All well-appearing newborn infants born to women given a diagnosis of chorioamnionitis by their obstetrical provider should undergo a
limited diagnostic evaluation (no lumbar puncture) and receive empirical antimicrobial therapy (AII).

- For all women who received adequate IAP defined as penicillin (preferred), ampicillin, or cefazolin (penicillin-allergic women at low risk of anaphylaxis) for 4 or more hours before delivery, their newborn infants require only routine care and observation in the hospital for 48 hours (BIII). If these infants meet other discharge criteria, including term birth and ready access to medical care, discharge can occur as early as 24 hours after birth with follow-up care by a care provider within 48 to 72 hours (CII).

- Well-appearing term newborn infants whose mothers received no or inadequate IAP (including clindamycin or vancomycin) and had rupture of membranes for less than 18 hours require only observation for 48 hours (BIII).

- Well-appearing term newborn infants born to women with no or inadequate IAP and rupture of membranes for 18 or more hours before delivery should undergo a “limited evaluation” (i.e., blood culture and CBC count with differential and platelets at birth) and observation for at least 48 hours (BIII).

- All preterm infants born to women with no or inadequate IAP should undergo a limited evaluation and observation for at least 48 hours (BIII).

**REFERENCES**


**LEAD AUTHORS**

Carol J. Baker, MD
Carrie L. Byington, MD
Richard A. Polin, MD

**COMMITTEE ON INFECTIOUS DISEASES, 2010–2011**

Michael T. Brady, MD, Chairperson
Henry H. Bernstein, DO
Carrie L. Byington, MD
Kathryn M. Edwards, MD
Margaret C. Fisher, MD
Mary P. Glode, MD
Mary Anne Jackson, MD
Harry L. Keyserling, MD
David W. Kimberlin, MD
Yvonne A. Maldonado, MD
Walter A. Orenstein, MD
Gordon E. Schutze, MD
Rodney E. Willoughby, MD

**LIAISONS**

Beth Bell, MD, MPH – Centers for Disease Control and Prevention
Robert Bortolussi, MD – Canadian Paediatric Society
Marc A. Fischer, MD – Centers for Disease Control and Prevention
Bruce Gellin, MD – National Vaccine Program Office
Richard L. Gorman, MD – National Institutes of Health
Lucia Lee, MD – Food and Drug Administration
R. Douglas Pratt, MD – Food and Drug Administration
Jennifer S. Read, MD – National Institutes of Health
Jeffrey R. Starke, MD – American Thoracic Society

Jack Swanson, MD – Committee on Practice Ambulatory Medicine
Tina Q. Tan, MD – Pediatric Infectious Diseases Society

**EX OFFICIO**

Carol J. Baker, MD – Red Book Associate Editor
Sarah S. Long, MD – Red Book Associate Editor
H. Cody Meissner, MD – Red Book Associate Editor
Larry K. Pickering, MD – Red Book Editor

**CONSULTANT**

Lorry G. Rubin, MD

**STAFF**

Jennifer Frantz, MPH

**COMMITTEE ON FETUS AND NEWBORN, 2010–2011**

Lu-Ann Papile, MD, Chairperson
James Cummings, MD
Jill E. Bailey, MD
Vinod K. Bhutani, MD
Waldemar A. Carlo, MD
Praveen Kumar, MD
Richard A. Polin, MD
Rosemarie C. Tan, MD, PhD
Kasper S. Wang, MD
Kristi L. Watterberg, MD

**LIAISONS**

Capt Wanda D. Barfield, MD, MPH – Centers for Disease Control and Prevention
William H. Barth Jr, MD – American College of Obstetricians and Gynecologists
Ann L. Jefferies, MD – Canadian Paediatric Society
Rosalie O. Mainous, PhD, RNC, NNP – National Association of Neonatal Nurses
Tonse N. K. Raja, MD, DCH – National Institutes of Health

**STAFF**

Jim Couto, MA


Recommendations for the Prevention of Perinatal Group B Streptococcal (GBS) Disease

COMMITTEE ON INFECTIOUS DISEASES AND COMMITTEE ON FETUS AND NEWBORN

Pediatrics originally published online August 1, 2011;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/early/2011/07/28/peds.2011-1466

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
https://shop.aap.org/licensing-permissions/

Reprints
Information about ordering reprints can be found online:
http://classic.pediatrics.aappublications.org/content/reprints
Recommendations for the Prevention of Perinatal Group B Streptococcal (GBS) Disease
COMMITTEE ON INFECTIOUS DISEASES AND COMMITTEE ON FETUS AND NEWBORN

*Pediatrics* originally published online August 1, 2011;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://pediatrics.aappublications.org/content/early/2011/07/28/peds.2011-1466